After-Hours Movers 7/7: AMGN, RT, ALKS, SHLM Higher; NEXM, XNPT,...

NexMed, Inc. (Nasdaq: NEXM) 64.1% LOWER; announced the mutual decision with Novartis (NYSE: NVS) to terminate the licensing agreement for NM100060, a topically-applied treatment for onychomycosis, commonly known as nail fungus.

NexMed entered into the exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060. Click here for the full report.

Amgen (Nasdaq: AMGN) 13.6% HIGHER; announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus...